Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants-Reference-Cited by-同舟云学术

Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants

Published:2018-08-28 Issue:10 Volume:109 Page:3224-3234
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Shiota Masaki¹^ORCID,Dejima Takashi¹,Yamamoto Yoshiaki²,Takeuchi Ario¹,Imada Kenjiro¹,Kashiwagi Eiji¹,Inokuchi Junichi¹,Tatsugami Katsunori¹,Kajioka Shunichi¹,Uchiumi Takeshi³,Eto Masatoshi¹

Affiliation:

1. Department of Urology; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

2. Department of Urology; Graduate School of Medicine; Yamaguchi University; Ube Japan

3. Department of Clinical Chemistry and Laboratory Medicine; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

Funder

Takeda Science Foundation

Shin-Nihon Foundation

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13751/fullpdf

Reference56 articles.

1. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer;Shiota;Int J Urol,2016

2. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

3. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

5. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate;Molecular Pharmaceutics;2024-01-17

2. Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer;iScience;2023-09

3. Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells;Cells;2023-08-11

4. Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer;2023-05-06

5. Preclinical Models of Neuroendocrine Prostate Cancer;Current Protocols;2023-05